SHORT COMMUNICATION. RAJIV KHANNA,*,2,3 SCOTT R. BURROWS,*,2 PATTY M. STEIGERWALD-MULLEN, SCOTT A. THOMSON,* MICHAEL G. KURILLA, and DENIS J.
|
|
- Stewart Derrick Todd
- 5 years ago
- Views:
Transcription
1 VIROLOGY 214, (1995) SHORT COMMUNICATION Isolation of Cytotoxic T Lymphocytes from Healthy Seropositive Individuals Specific for Peptide Epitopes from Epstein Barr Virus Nuclear Antigen 1: Implications for Viral Persistence and Tumor Surveillance 1 RAJIV KHANNA,*,2,3 SCOTT R. BURROWS,*,2 PATTY M. STEIGERWALD-MULLEN, SCOTT A. THOMSON,* MICHAEL G. KURILLA, and DENIS J. MOSS* *Queensland Institute of Medical Research, The Bancroft Centre, 300 Herston Road, Brisbane, Australia 4029; and Department of Pathology and Microbiology, University of Virginia, Charlottesville, Virginia Received July 24, 1995; accepted October 11, 1995 The question of whether Epstein Barr nuclear antigen 1 (EBNA1) includes cytotoxic T lymphocyte (CTL) epitopes has generated considerable scientific interest, primarily due to its important implications for the overall biology of Epstein Barr virus (EBV). Earlier studies have suggested that EBV-associated malignancies that express only EBNA1 escape virus-specific immune surveillance since this antigen is not a target for CTL recognition. In the present report we have used a modified protocol to demonstrate that EBNA1 includes sequences which can be recognized by both polyclonal and clonal CTLs. CD4 / CTL clones were isolated from a healthy, seropositive donor that recognized the peptide epitope TSLYNLRRGTALA from EBNA1 in association with HLA DR1. Interestingly, these CTLs are unable to lyse EBV-infected B cells suggesting that EBNA1 may not be endogenously processed and/or presented to the host CTL response. Despite recent suggestions that glycine alanine repeat sequences within EBNA1 can inhibit endogenous processing, target cells infected with recombinant vaccinia vectors encoding truncated EBNA1 proteins, without these repeat sequences, were not recognized by this CTL clone. Thus it seems that the presence of glycine alanine repeats is not responsible for inhibiting the processing of the class II-restricted epitope defined in this study. These results substantiate the view that EBV-infected normal and malignant cells, where viral gene expression is limited to EBNA1, can resist CTL-mediated immune surveillance in vivo Academic Press, Inc. Epstein Barr virus (EBV) is a member of the human herpesvirus family that maintains a life-long latent asso- ciation with B lymphocytes and a permissive association with stratified epithelium in the oropharynx (1, 2). Two types of EBV (1 and 2, also referred to as A and B) are recognized that show DNA sequence divergence within the BAM H1 WYH and E regions of the genome (3, 4). There is now convincing evidence that EBV-specific memory CD8 / and CD4 / cytotoxic T lymphocytes (CTL) are responsible for controlling the level of EBV-positive B lymphocytes which all healthy, seropositive individuals carry for life following primary infection with the virus (5 7). Previous studies have defined the relative distribution of CTL epitopes within EBV latent proteins recognized by T cells clones from healthy immune individuals expressing an array of MHC class I alleles (8 10). Using 1 A part of this work was presented at the CIBA Foundation Symposium on Vaccines against Virally Induced Cancers; March 15 17, These two authors contributed equally in this work and their order should be considered arbitrary. 3 To whom reprint requests should be addressed. Fax: ; rajivk@qimr.edu.au. recombinant vaccinia encoding each of the EBV nuclear antigens (EBNA) and latent membrane proteins (LMPs), numerous CTL epitopes were mapped within EBNA2-6 and LMP, while no CTL response was detected against EBNA1. The question of whether EBNA1 includes CTL epitopes has generated considerable scientific interest, primarily due to its important implications for the overall biology of EBV. First, it has been proposed that the EBV-associated tumor, Burkitt s lymphoma (BL), escapes virus-specific immune surveillance by restricting latent gene expression to EBNA1 (11). This view is reinforced by earlier studies which showed that BL patients retain detectable EBV-specific T cell surveillance, indicating that CTL dys- function is an unlikely cause of the outgrowth of these EBV-infected tumors in vivo (12). Second, it has recently been shown that EBV-infected B cells, expressing EBNA1 and LMP2a only, are capable of maintaining the latent viral infection in vivo (13). Third, an earlier study carried out by Trivedi and colleagues clearly showed that mammary carcinoma cells transfected with the EBNA1 gene were not rejected by histocompatible mice, whereas LMP-transfected cells were regularly rejected (14). Thus /95 $12.00 Copyright 1995 by Academic Press, Inc. All rights of reproduction in any form reserved.
2 634 SHORT COMMUNICATION ratio of 20:1). These polyclonal CTLs were tested against autologous phytohemagglutinin (PHA) blasts presensitized with an overlapping net of EBNA1 peptides (15-mer overlapping by 10 amino acids) as described earlier (15). Polyclonal CTLs from donors LC and DM, stimulated with autologous LCLs, recognized four different peptides from EBNA1. CTLs from donor LC showed reactivity against peptide 49 (RRGTALAIPQCRLTP), while CTLs from donor DM recognized autologous PHA blasts in the presence of peptides 30 (EPDVPPGAIEQGPAD), 47 (GGSKTSLYNLRRGTA), and 48 (SLYNLRRGTALAIPQ) (Figs. 1a and 1b). In contrast, CTLs from donors CM and NB showed no significant reactivity against any of the EBNA1 peptides (data not shown). These experiments were repeated with two different blood samples and consistently the same set of peptides was recognized by CTLs from donors DM and LC. To confirm the data obtained with polyclonal effectors, CTL clones were generated (16) from donors DM and LC by seeding UM cells or purified CD4 / T cells, after stimulation with either autologous LCLs or EBNA1 peptides (peptides 30, 47, and 48 for donor DM and peptide 49 for donor LC). CD4 / T cells were purified from fresh UM cells using a Lymphokwik reagent (One Lambda Inc., CA). Colonies were harvested after 3 days and amplified in culture with biweekly restimulation with ril-2 and autologous LCL precoated with EBNA1 peptide(s). Two CTL clones were isolated from donor DM (referred to as DM2 and DM6) following stimulation with peptide 48 (SLYNLR- FIG. 1. Identification of CTLs specific for EBNA1 peptides in healthy RGTALAIPQ). Clone DM2 was isolated from UM cells, seropositive individuals. Polyclonal CTLs from donor DM (a) and LC while DM6 was isolated using purified CD4 / T cells. (b) were used as effectors to test for reactivity against autologous These CTL clones showed strong T cell T cell killing PHA blasts presensitized with overlapping EBNA1 peptides. Results are expressed as percentage specific lysis observed in a standard 5- (17) in the presence of peptides GGSKTSLYNLRRGTA hr chromium-release assay. An effector to target ratio of 20:1 was used in the assay. it is plausible that some virus-infected B cells maintain a nonimmunogenic phenotype by down-regulating the critical latent proteins needed for CTL recognition. The present study was specifically designed to consider the possibility of detecting an EBNA1-specific CTL response in healthy EBV-seropositive individuals, since earlier studies have essentially drawn their conclusions on the basis of negative evidence. Unfractionated mononuclear (UM) cells (10 6 /ml) from EBV-seropositive donors LC (HLA A1, B8, B18, DR3, DR11), NB (A2, A24, B7, B35, DR11), CM (HLA A11, A24, B7, B44, DR1, DR4), and DM (A24, A29, B44, Bw47, DR1, DR7) were cultivated with irradiated (8000 R) autologous lymphoblastoid cell lines (LCLs) transformed with the type 1 EBV isolate, B95.8 (responder to stimulator ratio of 50:1) in 2-ml culture wells (Linbro) in RPMI 1640/10% FCS. After 7 days, cultures were restimulated with autolo- gous LCLs and on Day 10 the cells were used as effectors in a standard 51 Cr-release assay (effector:target FIG. 2. MHC restriction analysis for CTL clones. Peptide-coated DM PHA blasts were precoated with peptide 48 (SLYNLRRGTALAIPQ; 1 mg/ml) and then exposed to CTL clones (DM2 and DM6) in the presence of anti-class I (W6/32) or anti-class II (L243) antibody (1:20 diluted ascites). An effector to target ratio of 5:1 was used in the assay. Data from one representative experiment of three are shown.
3 SHORT COMMUNICATION 635 FIG. 3. Minimalizing the EBNA1 epitope. DM anti-cd40 B cell blasts were presensitized with individual overlapping peptides and then exposed to CTL clone DM2. The peptide sequence shown in a box was identified as the minimal epitope sequence required for maximal lysis. An effector to target ratio of 5:1 was used in the assay. Data from one representative experiment of two are shown. and SLYNLRRGTALAIPQ, suggesting that both these were synthesized and screened for recognition by DM2. overlapping sequences might include an EBNA1 epitope. As shown in Fig. 3, 10 different peptides were tested and No CTL clones specific for EBNA1 peptides were iso- compared for the concentration required for half-maximal lated from donors LC or DM following stimulation with lysis of autologous anti-cd40 B cell blasts. These B cell peptides 30 and 49. blasts were generated as described previously (18). Characterization (by FACS analysis) revealed that DM2 Based on this analysis, peptide TSLYNLRRGTALA was and DM6 were ú99.0% CD3 /, CD4 / cells, a phenotype the minimal peptide with maximal activity, inducing halfmaximal suggesting that these clones might be MHC class IIrestricted. lysis at a concentration of mg/ml. To examine this possibility, autologous PHA An important aspect of the characterization of the CTL blasts were presensitized with peptide 48 and then exposed clone was to determine whether DM2 could recognize to the CTL clones in the presence of anti-class I autologous LCLs transformed with a range of virus (W6/32) or anti-class II (L243) antibody. As shown in Fig. strains. These LCLs were established either spontane- 2, recognition of peptide 48-coated PHA blasts was ously (19) or by exogenous virus transformation of peripheral blocked by L243 but was not significantly affected by B cells using type 1 or 2 EBV isolates (16). Surprisblocked W6/32 antibody. This result confirmed that these CTL ingly, no LCLs were recognized by DM2 (Fig. 4). The lack clones are MHC class II-restricted. of CTL recognition by DM2 was not due to any defect in To minimalize this CTL epitope, overlapping peptides the expression of MHC class II alleles, since all LCLs FIG. 4. Recognition of DM LCLs transformed with either type 1 or type 2 EBV isolates by CTL clone DM2. An effector to target ratio of 5:1 was used in the assay. Data from one representative experiment of four are shown.
4 636 SHORT COMMUNICATION FIG. 5. HLA class II restriction analysis for CTL clone DM2. Allogeneic EBV-transformed LCLs, some sharing an MHC class II antigen with donor DM, were exposed to the CTL clone DM2 in the absence or presence of TSLYNLRRGTALA peptide. An effector to target ratio of 5:1 was used in the assay. Data from one representative experiment of two are shown. were efficiently recognized by the clone if presensitized Indeed, the sequence conforms to the previously pubwith the TSLYNLRRGTALA peptide. This result suggests lished HLA DR1 binding motif (20). that LCLs are unable to process and present the EBNA1 To determine whether the lack of CTL lysis of autolo- CTL epitope endogenously. gous LCLs by CTL clone DM2 was due to insufficient To define the HLA restriction of the CTL clone DM2, levels of EBNA1 expressed in these cells, DM/B95.8 a panel of allogeneic LCLs, some sharing an MHC class LCLs and DM CD40 B cell blasts were infected with II allele with donor DM, was presensitized with TSLYNL- recombinant vaccinia constructs encoding the full-length RRGTALA and tested in a standard 51 Cr-release assay. EBNA1 gene (Vacc.EBNA1) and vaccinia encoding T7 As shown in Fig. 5, peptide-sensitized LCLs from RNA polymerase (Vacc.T7) (8). Despite high levels of DR1/ve donors, but not DR10ve donors, were recog- EBNA1 expression in these cells as determined by immunized by CTL clone DM2. These results suggest that noblotting (data not shown), no lysis was seen in the peptide TSLYNLRRGTALA is restricted through HLA DR1. presence of CTL clone DM2 (Fig. 6). These results confirm that, although EBNA1 includes a CTL epitope, this epitope is not processed and presented endogenously by EBV-infected cells. Levitskaya and colleagues have recently demonstrated that repeat sequences of glycine alanine within EBNA1 can inhibit presentation of class I epitopes (21). To explore the possibility that the lack of endogenous processing of the TSLYNLRRGTALA epitope relates to the presence of these repeat sequences, DM target cells were infected with two recombinant vaccinia vectors (Vacc.E1DGA and E1DCGA). Each of these constructs encodes a truncated EBNA1 protein without the glycine alanine repeats but including this epitope (P. M. Steigewald-Mullen and M. G. Kurilla, submitted for publication). Interestingly, target cells expressing these proteins were FIG. 6. Functional analysis of CTL clone DM2 using autologous LCLs or CD40 B cells infected with recombinant vaccinia expressing fullthat the presence of glycine alanine repeats is not re- not recognized by CTL clone DM2 (Fig. 6). Thus it seems length EBNA1 (Vacc.EBNA1), truncated EBNA1 proteins with glycine alanine repeat sequences deleted (Vacc.E1DGA and Vacc.E1DCGA), sponsible for inhibiting the processing of the class IIor with the nuclear localization signal sequence deleted (Vacc.E1DSS), restricted epitope defined in this study. Another possible as target cells. TSLYNLRRGTALA peptide-coated LCLs and CD40 B reason for the inability of infected cells to endogenously cells were used as controls. An effector to target ratio of 5:1 was used in the assay. Data from one representative experiment of four are process this epitope is that EBNA1 localizes to the nu- shown. cleus, thus limiting class II presentation. However, this
5 SHORT COMMUNICATION 637 seems unlikely since target cells were also not recog- REFERENCES nized by DM2 CTLs after infection with a recombinant 1. Yao, Q. Y., Ogan, P., Rowe, M., Wood, M., and Rickinson, A. B., Int. vaccinia (Vacc.E1DSS) encoding the EBNA1 protein with J. Cancer 43, (1989). the nuclear localization signal sequence deleted (Fig. 6). 2. Greenspan, J. S., Greenspan, D., Lennette, E. T., Abrams, D. I., Furthermore, we have recently identified an epitope from Conant, M. A., Petersen, V., and Freese, U. K., N. Engl. J. Med. 313, (1985). another EBV nuclear antigen (EBNA2) which is efficiently 3. Sculley, T. B., Apolloni, A., Stumm, R., Moss, D. J., Mueller-Lantzsch, processed endogenously through the class II pathway N., Misko, I. S., and Cooper, D. A., Virology 171, (1989). (manuscript in preparation). 4. Sample, J., and Kieff, E., J. Virol. 64, (1990). The present study clearly demonstrates that EBNA1 5. Moss, D. J., Rickinson, A. B., and Pope, J. H., Int. J. Cancer 22, 662 includes sequences which can be recognized by both 668 (1978). 6. Moss, D. J., Rickinson, A. B., and Pope, J. H., Int. J. Cancer 23, 618 polyclonal and clonal CTLs (Figs. 1 and 2). Interestingly, 625 (1979). the HLA DR1-restricted CTL clones are unable to recog- 7. Misko, I. S., Soszynski, T. D., Kane, R. G., and Pope, J. H., Clin. nize EBV-infected B cells, suggesting that EBNA1 may Immunol. Immunopathol. 32, (1984). have evolved a mechanism to avoid endogenous pro- 8. Khanna, R., Burrows, S. R., Kurilla, M. G., Jacob, C. A., Misko, I. S., cessing and/or presentation through the class II path- Sculley, T. B., Kieff, E., and Moss, D. J., J. Exp. Med. 176, (1992). way. The presence of memory CTLs specific for EBNA1 9. Murray, R. J., Kurilla, M. G., Brooks, J. M., Thomas, W. A., Rowe, peptide epitopes and their activation in vitro following M., Kieff, E., and Rickinson, A. B., J. Exp. Med. 176, LCL stimulation (Fig. 1), however, suggests that EBNA1 (1992). protein from EBV-infected cells might be exogenously 10. Brooks, J. M., Murray, R. J., Thomas, W. A., Kurilla, M. G., and endocytosed by professional antigen-presenting cells Rickinson, A. B., J. Exp. Med. 178, (1993). 11. Rowe, M., Rowe, D. T., Gregory, C. D., Young, L. S., Farrell, P. J., and presented in association with MHC class II moleand Rupani, H., EMBO J. 6, (1987). cules. Alternatively, epitopes generated via extracellular 12. Rooney, C. M., Rickinson, A. B., Moss, D. J., Lenoir, G. M., and cleavage of EBNA1 by serum proteases might be respon- Epstein, M. A., IARC Sci. Publ (1985). sible for the activation of CTLs. It is also possible that 13. Chen, F., Zou, J. Z., di Renzo, L., Winberg, G., Hu, F., Klein, E., Klein, these CTLs have been activated in vivo by EBV-infected E., and Ernberg, I., J. Virol. 69, (1995). 14. Trivedi, P., Masucci, M. G., Winberg, G., and Klein, G., Int. J. Cancer cells other than B cells. Indeed, earlier studies have 48, (1991). shown that the efficiency of endogenous processing of 15. Burrows, S. R., Gardner, J., Khanna, R., Steward, T., Moss, D. J., class II epitopes is often dependent on the cell lineage Rodda, S., and Suhrbier, A., J. Gen. Virol. 75, (1994). of the antigen-presenting cell (22). The results of the 16. Moss, D. J., Misko, I. S., Burrows, S. R., Burman, K., McCarthy, R., present study substantiate the view that EBV can persist and Sculley, T. B., Nature 331, (1988). 17. Burrows, S. R., Suhrbier, A., Khanna, R., and Moss, D. J., Immunolin normal and malignant cells in vivo in an immunologiogy 76, (1992). cally silent state. 18. Khanna, R., Jacob, C. A., Burrows, S. R., and Moss, D. J., J. Immunol. Methods 164, (1993). 19. Rickinson, A. B., Rowe, M., Hart, I. J., Yao, Q. Y., Henderson, L. E., ACKNOWLEDGMENTS Rabin, H., and Epstein, M. A., Cell Immunol. 87, (1984). 20. Chicz, R. M., Urban, R. G., Lane, W. S., Gorga, J. C., Stern, L. J., We acknowledge the Cetus Corporation for the generous gift of ril- Vignali, D. A., and Strominger, J. L., Nature 358, (1992). 2. This work was supported by grants from Queensland Cancer Fund 21. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, and the National Cancer Institute (U.S.A.; CA ). M.G.K. is a P. M., Klein, G., Kurilla, M. G., and Masucci, M. G., Nature scholar of the Lucille P. Markey Charitable Trust. P.M.S.M. is supported 375, (1995). by the Medical Scientist Training Program of the University of Virginia 22. Moreno, J., Vignali, D. A., Nadimi, F., Fuchs, S., Adorini, L., and Health Sciences Center. Hammerling, G. J., J. Immunol. 147, (1991).
RAJIV KHANNA, 1 * SCOTT R. BURROWS, 1 ANNE NEISIG, 2 JACQUES NEEFJES, 2 DENIS J. MOSS, 1 AND SHARON L. SILINS 1
JOURNAL OF VIROLOGY, Oct. 1997, p. 7429 7435 Vol. 71, No. 10 0022-538X/97/$04.00 0 Copyright 1997, American Society for Microbiology Hierarchy of Epstein-Barr Virus-Specific Cytotoxic T-Cell Responses
More informationReceived 11 August 1997/Accepted 20 November 1997
JOURNAL OF VIROLOGY, Mar. 1998, p. 2246 2252 Vol. 72, No. 3 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted
More informationNumber of Patients Susceptibility Reference HLA-A* (278 EBV+) Increased incidence of. [1] EBV + chl 516 (192 EBV+) Increased incidence of
Supporting Information: Table S1. Previously published HLA-class I associations with. Number of Patients Susceptibility Reference HLA-A*01 934 (278 EBV+) Increased incidence of [1] 516 (192 EBV+) Increased
More informationThe Journal of Experimental Medicine
Endogenous Presentation of CD8 T Cell Epitopes from Epstein-Barr Virus encoded Nuclear Antigen 1 Judy Tellam, Geoff Connolly, Katherine J. Green, John J. Miles, Denis J. Moss, Scott R. Burrows, and Rajiv
More informationReceived 24 July 2001/Accepted 12 November 2001
JOURNAL OF VIROLOGY, Feb. 2002, p. 1914 1921 Vol. 76, No. 4 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.4.1914 1921.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. RelB Nuclear
More informationA-type and B-type Epstein Barr virus differ in their ability to spontaneously enter the lytic cycle
Journal of General Virology (1999), 80, 441 445. Printed in Great Britain... SHORT COMMUNICATION A-type and B-type Epstein Barr virus differ in their ability to spontaneously enter the lytic cycle M. Buck,
More informationDecreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated
Decreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated nasopharyngeal carcinoma Mark H. Fogg a, Lori J. Wirth b, Marshall Posner b, and Fred Wang a,1 a Department of Medicine,
More informationEBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham
EBV Infection and Immunity Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Introduction Large ds DNA virus Spread by saliva contact Lifelong infection Predominantly B-lymphotropic
More informationDetermination of the temporal pattern and importance of BALF1 expression in Epstein-Barr viral infection
Determination of the temporal pattern and importance of BALF1 expression in Epstein-Barr viral infection Melissa Mihelidakis May 6, 2004 7.340 Research Proposal Introduction Apoptosis, or programmed cell
More informationClinical implications of Epstein-Barr virus strain diversity
Mini Review Open Access Clinical implications of Epstein-Barr virus strain diversity Ana Cirac 1,2,3, Uta Behrends 1,2,3, and Josef Mautner 1,2,3 * 1 Children s Hospital, Technische Universität München,
More informationYamaguchi University School of Medicine, Kogushi, Ube, Yamaguchi. growth in low serum, anchorage-independent growth in soft
JOURNAL OF VIROLOGY, Sept. 1994, p. 6069-6073 Vol. 68, No. 9 0022-538X/94/$04.00+0 Copyright 1994, American Society for Microbiology Isolation of Epstein-Barr Virus (EBV)-Negative Cell Clones from the
More informationEpstein-Barr virus, a -herpesvirus widespread in human
Published Online: 5 May, 1997 Supp Info: http://doi.org/10.1084/jem.185.9.1605 Downloaded from jem.rupress.org on April 25, 2018 Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the
More informationMATERIALS AND METHODS
Proc. Natl. Acad. Sci. USA Vol. 96, pp. 10391 10396, August 1999 Medical Sciences Activation and adoptive transfer of Epstein Barr virus-specific cytotoxic T cells in solid organ transplant patients with
More informationEBV infection B cells and lymphomagenesis. Sridhar Chaganti
EBV infection B cells and lymphomagenesis Sridhar Chaganti How EBV infects B-cells How viral genes influence the infected B cell Differences and similarities between in vitro and in vivo infection How
More informationDefinition of an Epitope on NS3 Recognized by Human CD4 Cytotoxic T Lymphocyte Clones Cross-Reactive for Dengue Virus Types 2, 3, and 4
VIROLOGY 240, 169 174 (1998) ARTICLE NO. VY978925 Definition of an Epitope on NS3 Recognized by Human CD4 Cytotoxic T Lymphocyte Clones Cross-Reactive for Dengue Virus Types 2, 3, and 4 Ichiro Kurane,*
More informationType 2 Cytokines Predominate in the Human CD4 T-Lymphocyte Response to Epstein-Barr Virus Nuclear Antigen 1
JOURNAL OF VIROLOGY, Aug. 2000, p. 6748 6759 Vol. 74, No. 15 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Type 2 Cytokines Predominate in the Human CD4
More informationRecognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E specific CD8 T cell clone
Cancer Immun 1424-9634Academy of Cancer Immunology Cancer Immunity (30 June 2006) Vol. 6, p. 9 Submitted: 2 September 2005. Resubmitted: 28 April 2006. Accepted: 2 June 2006. Copyright 2006 by Mayumi Nakagawa
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationAdministration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas
Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas CM. Bollard, G Dotti, S Gottschalk, E Liu, A Sheehan, M Mims, H Liu, AP. Gee,
More informationEpstein Barr Virus Unit, Queensland Institute of Medical Research, The Bancroft Centre, 300 Herston Road, Brisbane, Queensland 4029, Australia
International Immunology, Vol. 9, No. 11, pp. 1745 1755 1997 Oxford University Press Selection of a diverse TCR repertoire in response to an Epstein Barr virus-encoded transactivator protein BZLF1 by CD8
More informationNovel Approach to the Formulation of an Epstein-Barr Virus Antigen-Based Nasopharyngeal Carcinoma Vaccine
JOURNAL OF VIROLOGY, Jan. 2010, p. 407 417 Vol. 84, No. 1 0022-538X/10/$12.00 doi:10.1128/jvi.01303-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Novel Approach to the Formulation
More informationInfection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases
584 Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases Michael P. Pender Department of Medicine, The University of Queensland, Clinical Sciences Building, Royal Brisbane
More informationTranslating EBV Immunology from Bench to Bedside: Somnium Animadverto A Dream Realized
Translating EBV Immunology from Bench to Bedside: Somnium Animadverto A Dream Realized Epstein-Barr Virus Human herpesvirus 90% population infected Associated with many other cancers latent infection.persists
More informationCellular & Molecular Immunology 229
Cellular & Molecular Immunology 229 Combined Transfection with EBV-Specific Epitopes and HLA-A2 genes is More Effective than Separate Transfection in Promoting CTL Lysis against Nasopharyngeal Carcinoma
More informationInfection of Autoreactive B Lymphocytes with EBV, Causing Chronic Autoimmune Diseases
Infection of Autoreactive B Lymphocytes with EBV, Causing Chronic Autoimmune Diseases Michael P. Pender (Department of Medicine, The University of Queensland, Clinical Sciences Building, Royal Brisbane
More informationHuman CD4 T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen EBNA1
Human CD4 T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen EBNA1 By Christian Münz,* Kara L. Bickham,* Marion Subklewe,* Ming L. Tsang,* Ann Chahroudi,* Michael G. Kurilla,
More informationHuman Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells
Human Cytomegalovirus Latency-Associated Proteins Elicit Immune-Suppressive IL-10 Producing CD4 + T Cells Gavin M. Mason, Sarah Jackson, Georgina Okecha, Emma Poole, J. G. Patrick Sissons, John Sinclair,
More information1 Introduction. Rajiv Khanna 1, Sharon L. Silins 1, Zhiping Weng 2, David Gatchell 2, Scott R. Burrows 1 and Leanne Cooper 1
Eur. J. Immunol. 1999. 29: 1587 1597 MHC-peptide-TCR interactions in HLA cross-restriction 1587 Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence
More informationHerpesviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Herpesviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped icosahedral capsid (T=16), diameter 125 nm Diameter of enveloped virion 200 nm Capsid
More informationDetermining virological, serological and immunological parameters of EBV infection in the development of PTLD
International Immunology, Vol. 16, No. 7, pp. 983±989 doi: 10.1093/intimm/dxh099 Advance Access publication May 24, 2004 ã 2004 The Japanese Society for Immunology Determining virological, serological
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/22278 holds various files of this Leiden University dissertation. Author: Cunha Carvalho de Miranda, Noel Filipe da Title: Mismatch repair and MUTYH deficient
More informationCytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
More informationEpstein- Barr Virus In Iraqi Patients With Nasopharangeal Carcinoma
Epstein THE IRAQI Barr Virus POSTEGRADUATE in Iraqi Patient MEDICAL JOURNAL Batool VOL.5, M.Mahdi NO.2,2006, etal. Epstein- Barr Virus In Iraqi Patients With Nasopharangeal Carcinoma Batool Mutar Mahdi
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationHuman CD8 T Cell Responses to EBV EBNA1: HLA Class I Presentation of the (Gly-Ala) Containing Protein Requires Exogenous Processing
Immunity, Vol. 7, 791 802, December, 1997, Copyright 1997 by Cell Press Human CD8 T Cell Responses to EBV EBNA1: HLA Class I Presentation of the (Gly-Ala) Containing Protein Requires Exogenous Processing
More informationAntigen Presentation to T lymphocytes
Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antigen processing: How are
More informationEvolution of Two Types of Rhesus Lymphocryptovirus Similar to Type 1 and Type 2 Epstein-Barr Virus
JOURNAL OF VIROLOGY, Nov. 1999, p. 9206 9212 Vol. 73, No. 11 0022-538X/99/$04.00 0 Evolution of Two Types of Rhesus Lymphocryptovirus Similar to Type 1 and Type 2 Epstein-Barr Virus YOUNG-GYU CHO, 1 ALEXEY
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More informationJOURNAL OF VIROLOGY, Feb. 1999, p Vol. 73, No. 2. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Feb. 1999, p. 965 975 Vol. 73, No. 2 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Epstein-Barr Virus Nuclear Antigen 1 Sequences in
More informationCritical role of EBNA1-specific CD4 + T cells in the control of mouse Burkitt lymphoma in vivo
Research article Critical role of EBNA1-specific CD4 + T cells in the control of mouse Burkitt lymphoma in vivo Tihui Fu, Kui Shin Voo, and Rong-Fu Wang The Center for Cell and Gene Therapy and Department
More informationRestriction of Epstein-Barr Virus-Specific Cytotoxic T Cells by HLA-A,-B, and-c Molecules
Restriction of Epstein-Barr Virus-Specific Cytotoxic T Cells by HLA-A,-B, and-c Molecules Benjamin P. Chen, Valery Lam, Eric E. Kraus, Robert DeMars, and Paul M. Sondel ABSTRACT: HLA-loss variants of an
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationProduct Datasheet. HLA ABC Antibody (W6/32) NB Unit Size: 0.25 mg. Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22
Product Datasheet HLA ABC Antibody (W6/32) NB100-64775 Unit Size: 0.25 mg Store at -20C. Avoid freeze-thaw cycles. Reviews: 1 Publications: 22 Protocols, Publications, Related Products, Reviews, Research
More informationGeneral information. Cell mediated immunity. 455 LSA, Tuesday 11 to noon. Anytime after class.
General information Cell mediated immunity 455 LSA, Tuesday 11 to noon Anytime after class T-cell precursors Thymus Naive T-cells (CD8 or CD4) email: lcoscoy@berkeley.edu edu Use MCB150 as subject line
More informationDirect killing of Epstein-Barr virus (EBV) infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1
IMMUNOBIOLOGY Direct killing of Epstein-Barr virus (EBV) infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1 Elise Landais, Xavier Saulquin, Emmanuel Scotet, Lydie Trautmann, Marie-Alix
More informationBy Amy P. Sing, Richard F. Ambinder, Doley J. Hong, Michael Jensen, Wendy Batten, Effie Petersdorf, and Philip D. Greenberg
Isolation of Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes That Lyse Reed-Sternberg Cells: Implications for Immune-Mediated Therapy of EBV " Hodgkin s Disease By Amy P. Sing, Richard F. Ambinder,
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationConservation of Epstein-Barr Virus Cytotoxic T-Cell Epitopes in Posttransplant Lymphomas
American Journal of Pathology, Vol. 160, No. 5, May 2002 Copyright American Society for Investigative Pathology Conservation of Epstein-Barr Virus Cytotoxic T-Cell Epitopes in Posttransplant Lymphomas
More informationC. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.
Immunology - Problem Drill 13: T- Cell Mediated Immunity Question No. 1 of 10 1. During Antibody-dependent cell mediated cytotoxicity (ADCC), the antibody acts like a bridge between the specific antigen
More informationEBV Infection. > Cellular Immune Response Profiling. > Humoral Immune Response Profiling EBV. ImmunoTools
EBV ImmunoTools Peptide Tools to Study EBV EBV Infection > Cellular Immune Response Profiling Antigen spanning EBV PepMix Peptide Pools PepMix Collection EBV > Humoral Immune Response Profiling EBV RepliTope
More informationInhibition of Antigen Presentation by the Glycine/Alanine Repeat Domain Is Not Conserved in Simian Homologues of Epstein-Barr Virus Nuclear Antigen 1
JOURNAL OF VIROLOGY, Sept. 1999, p. 7381 7389 Vol. 73, No. 9 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Inhibition of Antigen Presentation by the Glycine/Alanine
More informationEpstein-Barr virus and immunity
Epstein-Barr virus and immunity Elena Kashuba, PhD Associate Professor Department of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institutet 1 Epstein-Barr virus EBV Everybody s virus 200 nm Enveloped
More informationExpression of Epstein-Barr Virus Gene and Clonality of Infiltrated T Lymphocytes in Epstein-Barr Virus-associated Gastric Carcinoma
DOI 10.4110/in.2011.11.1.50 pissn 1598-2629 eissn 2092-6685 ORIGINAL ARTICLE Expression of Epstein-Barr Virus Gene and Clonality of Infiltrated T Lymphocytes in Epstein-Barr Virus-associated Gastric Carcinoma
More informationCellular Pathology of immunological disorders
Cellular Pathology of immunological disorders SCBM344 Cellular and Molecular Pathology Witchuda Payuhakrit, Ph.D (Pathobiology) witchuda.pay@mahidol.ac.th Objectives Describe the etiology of immunological
More informationImmunotherapy in Treating Nasopharyngeal Carcinoma. Dora Kwong Department of Clinical Oncology Queen Mary Hospital The University of Hong Kong
Immunotherapy in Treating Nasopharyngeal Carcinoma Dora Kwong Department of Clinical Oncology Queen Mary Hospital The University of Hong Kong Disclosure Received honorarium from Merck Sharp & Dohme (MSD)
More informationMucosal Immune System
Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationK R N Baumforth, L S Young, K J Flavell, C Constandinou, P G Murray
J Clin Pathol: Mol Pathol 1999;52:307 322 307 Demystified... Biomedical Research Laboratories, School of Health Sciences, University of Wolverhampton, Wolverhampton WV1 1DJ, UK K R N Baumforth K J Flavell
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationEpstein-Barr Virus Polypeptides: Identification of Early Proteins and Their Synthesis and Glycosylation
JOURNAL OF VIROLOGY, Aug. 1981, p. 651-655 0022-538X/81/080651-05$02.00/0 Vol. 39, No. 2 Epstein-Barr Virus Polypeptides: Identification of Early Proteins and Their Synthesis and Glycosylation ROBERT J.
More informationAdaptive Immune System
Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationDeveloping Understanding of CMI. Dr Tom Wilkinson Associate Professor of Respiratory Medicine Faculty of Medicine University of Southampton UK
Pre-existing influenza-specific CD4+ T cells correlate with homologous and heterotypic response and disease protection against influenza challenge in humans Do At Risk Groups Rely more on CMI to Viruses?
More informationRole of De Novo Protein Synthesis in Target Cells Recognized by Cytotoxic T Lymphocytes Specific for Vesicular Stomatitis Virus
JOURNAL OF VIROLOGY, Dec. 1991, p. 6856-6861 22-538X/91/126856-6$2./ Copyright 1991, American Society for Microbiology Vol. 65, No. 12 Role of De Novo Protein Synthesis in Target Cells Recognized by Cytotoxic
More informationIdentification of the Site of Epstein-Barr Virus Persistence In Vivo as a Resting B Cell
JOURNAL OF VIROLOGY, July 1997, p. 4882 4891 Vol. 71, No. 7 0022-538X/97/$04.00 0 Copyright 1997, American Society for Microbiology Identification of the Site of Epstein-Barr Virus Persistence In Vivo
More informationVaccine Design: A Statisticans Overview
GoBack : A Statisticans Overview. Surajit Ray sray@samsi.info Surajit Ray Samsi PostDoc Seminar: Nov 2: 2004 - slide #1 The Chinese are credited with making the observation that deliberately infecting
More informationDownloaded by on April 28, 2018 https://pubs.acs.org Publication Date: April 24, 1984 doi: /bk
1 Virus-Receptor Interactions BERNARD N. FIELDS Department of Microbiology and Molecular Genetics, Harvard Medical School, and Department of Medicine (Infectious Disease), Brigham and Women's Hospital,
More informationLAB 1, Immunology. Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007
LAB 1, Immunology Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007 QUANTIFICATION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY AND DETECTION OF FAS/TRAILR INDUCED APOPTOSIS RESPONSIBLE:
More informationMinor H Antigen-Specific T Cells -The Black Box of the GVL Effect
Minor H Antigen-Specific T Cells -The Black Box of the GVL Effect All Allogeneic Stem Cell Transplants Are Blind Doctor Donor Patient Genetic polymorphism gives rise to unique peptides in donor and recipient
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationPractical Solution: presentation to cytotoxic T cells. How dendritic cells present antigen. How dendritic cells present antigen
Christian Kurts Institutes of Molecular Medicine and Experimental Immunology University of Bonn, Germany - presentation and (CTL) activation - I presentation and CD4 + T cell (Th cell) activation Different
More informationDefensive mechanisms include :
Acquired Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated immunity Humoral immunity Two mechanisms 1) Humoral
More informationThe Major Histocompatibility Complex (MHC)
The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationEpstein Barr virus (EBV) establishes a life-long, persistent,
Tonsillar memory B cells, latently infected with Epstein Barr virus, express the restricted pattern of latent genes previously found only in Epstein Barr virus-associated tumors Gregory J. Babcock and
More informationCHAPTER 18: Immune System
CHAPTER 18: Immune System 1. What are four characteristics of the specific immune system? a. b. c. d. 2. List the two main types of defense mechanisms and briefly describe features of each. 3. Give examples
More informationNIH Public Access Author Manuscript Cytotherapy. Author manuscript; available in PMC 2012 May 1.
NIH Public Access Author Manuscript Published in final edited form as: Cytotherapy. 2011 May ; 13(5): 518 522. doi:10.3109/14653249.2011.561983. Manufacture of GMP-grade Cytotoxic T Lymphocytes specific
More informationPersistent Infections
Persistent Infections Lecture 17 Biology 3310/4310 Virology Spring 2017 Paralyze resistance with persistence WOODY HAYES Acute vs persistent infections Acute infection - rapid and self-limiting Persistent
More informationSupplemental Table 1. CD8 + and CD4 + T cell epitopes identified in EBV lytic and latent cycle proteins. CD8 + T cell epitopes.
Supplemental Table 1. CD8 + and CD4 + T cell epitopes identified in EBV lytic and latent cycle proteins. CD8 + T cell epitopes EBV Antigen Epitope Coordinates Epitope Sequence HLA Restriction References
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationCOURSE: Medical Microbiology, MBIM 650/720 - Fall TOPIC: Antigen Processing, MHC Restriction, & Role of Thymus Lecture 12
COURSE: Medical Microbiology, MBIM 650/720 - Fall 2008 TOPIC: Antigen Processing, MHC Restriction, & Role of Thymus Lecture 12 FACULTY: Dr. Mayer Office: Bldg. #1, Rm B32 Phone: 733-3281 Email: MAYER@MED.SC.EDU
More informationCitation Acta medica Nagasakiensia. 1991, 36
NAOSITE: Nagasaki University's Ac Title Author(s) Induction of Killer Activity in Per Chemotherapy with Methotrexate, Vin (M-VAC) Taniguchi, Keisuke Citation Acta medica Nagasakiensia. 1991, 36 Issue Date
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke,. CONTRACTING ORGANIZATION: Johns Hopkins
More informationJefferson Digital Commons
Thomas Jefferson University Jefferson Digital Commons Department of Medical Oncology Faculty Papers Department of Medical Oncology December 2007 In vitro methods for generating highly purified EBV associated
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationMechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI
Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI Problems Virus escape from immune recognition Antagonism of T cell responses Peptide-MHC-TCR interaction T cell antagonism Variants of
More informationThe Innate Immune Response
The Innate Immune Response FUNCTIONS OF THE IMMUNE SYSTEM: Recognize, destroy and clear a diversity of pathogens. Initiate tissue and wound healing processes. Recognize and clear damaged self components.
More informationLecture 6. Burr BIO 4353/6345 HIV/AIDS. Tetramer staining of T cells (CTL s) Andrew McMichael seminar: Background
Lecture 6 Burr BIO 4353/6345 HIV/AIDS Andrew McMichael seminar: Background Tetramer staining of T cells (CTL s) 1. Vβ 19: There are 52 T cell receptor (TCR) Vβ gene segments in germ line DNA (See following
More informationThe present approach to this question draws upon information
JOURNAL OF VIROLOGY, Nov. 1994, p. 7374-7385 Vol. 68, No. 11 0022-538X/94/$04.00+0 Copyright D 1994, American Society for Microbiology Epstein-Barr Virus Latency in Blood Mononuclear Cells: Analysis of
More informationProfiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009
Profiling HLA motifs by large scale peptide sequencing 2009 Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 HLA Background The human leukocyte antigen system (HLA) is the
More informationEpstein-Barr Virus and the Somatic Hypermutation of Immunoglobulin Genes in Burkitt s Lymphoma Cells
JOURNAL OF VIROLOGY, Nov. 2001, p. 10488 10492 Vol. 75, No. 21 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.21.10488 10492.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Epstein-Barr
More informationLecture 11. Immunology and disease: parasite antigenic diversity
Lecture 11 Immunology and disease: parasite antigenic diversity RNAi interference video and tutorial (you are responsible for this material, so check it out.) http://www.pbs.org/wgbh/nova/sciencenow/3210/02.html
More information7.012 Quiz 3 Answers
MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel Friday 11/12/04 7.012 Quiz 3 Answers A > 85 B 72-84
More information